Mission Bio Transfers First Tapestri GMP-Ready CGT Assay to Avance Biosciences

February 04, 2022
 Mission Bio Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis developed by UCSF researcher Adam Abate, announced today the first tech transfer of a clinical trial-ready cell and gene therapy (CGT) assay from its Tapestri Platform to Avance Biosciences, Inc., a leading-...

UCSF cancer biologist Hani Goodarzi receives Vilcek Prize for Creative Promise

February 04, 2022
The Vilcek Foundation recognizes and celebrates the research contributions of computational biologist and cancer researcher Hani Goodarzi in a new article and video published on the foundation's website, Hani Goodarzi: A multidisciplinary approach to cancer biology. MORE

3 Researchers Named 2021 Fellows of American Association for the Advancement of Science

By Nina Bai on January 27, 2022
Three UC San Francisco researchers have been selected as 2021 fellows of the American Association for the Advancement of Science (AAAS), the world largest multidisciplinary scientific society and a leading publisher of cutting-edge research through its Science family of journals.  MORE

Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded

January 26, 2022
Akili Interactive, a leading digital medicine company developing cognitive treatments through game-changing technologies based on Adam Gazzaley's University of California, San Francisco research, has entered into a definitive agreement to become publicly traded via a merger with Social Capital...

ArsenalBio Announces Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors

January 11, 2022
Bristol Myers Squibb exercises option to initiate new program under the December 2020 agreement. Strategic collaboration combines ArsenalBio’s programmable cell therapy approach with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development.  

Sorting Cancers by ‘Immune Archetypes’ May Offer New Approach For Precision Immunotherapies

January 06, 2022
UCSF Researchers Uncover Common Immune Microenvironments Across Different Types of Cancer MORE

QSant, the first urine test for kidney transplant rejection, Featured at Biotech Showcase Digital 2022

January 04, 2022
NephroSant, a biotechnology company launched on University of California, San Francisco technology, and dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, announced that it will present a company overview at the upcoming Biotech Showcase conference...

See With Your Ears

December 22, 2021
Scott Harris, a UCSF Neuroscience PhD Candidate, Brings Home The Blackstone LanchPad Prize

Global Blood Therapeutics granted FDA label expansion for sickle cell disease therapy

December 20, 2021
Global Blood Therapeutics is trading higher after the FDA expanded the approval for the company’s sickle cell disease therapy Oxbryta (voxelotor), allowing its use in children as young as four years of age. Oxbryta, discovered by Matthew Jacobson, chair of the Department of Pharmaceutical Chemistry...

Neuvivo Launches to Develop Effective Treatments for ALS

December 09, 2021
Neuvivo, Inc., a company developing clinical-stage treatments for ALS and other neurodegenerative diseases based on the University of California, San Francisco lab discoveries by co-founder Michael McGrath, today announced its corporate launch, the expansion of its executive team, and the creation...